Published in J Am Coll Cardiol on March 01, 1998
Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A (1998) 3.23
Preservation of NO production by statins in the treatment of heart failure. Cardiovasc Res (2003) 1.59
Simvastatin Attenuates Oxidative Stress, NF-κB Activation, and Artery Calcification in LDLR-/- Mice Fed with High Fat Diet via Down-regulation of Tumor Necrosis Factor-α and TNF Receptor 1. PLoS One (2015) 1.43
Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol (2003) 1.30
Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep (2003) 1.11
Carotid artery atherosclerosis: effect of intensive lipid therapy on the vasa vasorum--evaluation by using dynamic contrast-enhanced MR imaging. Radiology (2011) 1.08
A robust rabbit model of human atherosclerosis and atherothrombosis. J Lipid Res (2009) 1.06
Pretreatment with simvastatin reduces myocardial no-reflow by opening mitochondrial K(ATP) channel. Br J Pharmacol (2006) 0.99
3-Hydroxy-3-methylglutaryl CoA reductase inhibitors up-regulate transforming growth factor-beta signaling in cultured heart cells via inhibition of geranylgeranylation of RhoA GTPase. Proc Natl Acad Sci U S A (1999) 0.99
Pravastatin and endothelium dependent vasomotion after coronary angioplasty: the PREFACE trial. Heart (2001) 0.96
Effect of statin therapy on the progression of coronary atherosclerosis. BMC Cardiovasc Disord (2012) 0.94
Vascular and valvar calcification: recent advances. Heart (2001) 0.94
Are statins anti-inflammatory? Curr Control Trials Cardiovasc Med (2000) 0.92
Statins and the role of nitric oxide in chronic heart failure. Heart Fail Rev (2003) 0.92
New insights into atherosclerotic plaque rupture. Postgrad Med J (2001) 0.90
Bicuspid aortic valve disease: the role of oxidative stress in Lrp5 bone formation. Cardiovasc Pathol (2011) 0.90
Statins in traumatic brain injury. Neurotherapeutics (2010) 0.89
Statins in heart failure: do we need another trial? Vasc Health Risk Manag (2013) 0.88
Atherogenesis: current understanding of the causes of atheroma. Heart (2000) 0.85
Cholesterol lowering and coronary artery disease: mechanisms of risk reduction. Heart (1998) 0.81
Macrophage Polarization in AIDS: Dynamic Interface between Anti-Viral and Anti-Inflammatory Macrophages during Acute and Chronic Infection. J Clin Cell Immunol (2015) 0.79
Role of endothelial nitric oxide in cerebrovascular regulation. Curr Pharm Biotechnol (2011) 0.79
Compliance of the aorta in two diseases affecting vascular elasticity, familial hypercholesterolemia and diabetes: a MRI study. Vasc Health Risk Manag (2008) 0.78
Therapeutic effect of carotid artery stenting versus endarterectomy for patients with high-risk carotid stenosis. Int J Clin Exp Med (2014) 0.75
Beneficial effects of soy supplementation on postmenopausal atherosclerosis are dependent on pretreatment stage of plaque progression. Menopause (2015) 0.75
Early decrease in carotid plaque lipid content as assessed by magnetic resonance imaging during treatment of rosuvastatin. BMC Cardiovasc Disord (2014) 0.75
[Non-lipid effects of statins: myth or fact?]. Wien Med Wochenschr (2003) 0.75
Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell (1998) 7.46
Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest (1994) 7.25
PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells. Cell (1989) 6.26
Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest (1995) 5.09
Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest (2000) 4.79
Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol (1987) 3.61
Are drugs within a class interchangeable? Lancet (1999) 3.58
Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation (2001) 3.47
Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. Am J Pathol (1986) 3.35
Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature (1998) 3.31
Cardiac cycle-dependent changes in aortic area and distensibility are reduced in older patients with isolated diastolic heart failure and correlate with exercise intolerance. J Am Coll Cardiol (2001) 3.18
Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest (1998) 3.17
Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol (1998) 3.04
Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. Circulation (2000) 2.94
Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation (2001) 2.80
An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb (1993) 2.77
The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci (2001) 2.75
Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation (1999) 2.73
Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol (1996) 2.68
Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol (2001) 2.63
Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation (1998) 2.63
Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci U S A (1997) 2.56
Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1 beta-converting enzyme. Am J Pathol (1995) 2.54
Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation (2001) 2.53
Cutting edge: heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells. J Immunol (2000) 2.50
Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res (1994) 2.46
Utility of fast cine magnetic resonance imaging and display for the detection of myocardial ischemia in patients not well suited for second harmonic stress echocardiography. Circulation (1999) 2.42
Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res (1998) 2.39
Human vascular smooth muscle cells. Target for and source of tumor necrosis factor. J Immunol (1989) 2.39
Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation (1999) 2.33
Reduction of experimental myocardial infarct size by corticosteroid administration. J Clin Invest (1973) 2.28
Inducible interleukin-1 gene expression in human vascular smooth muscle cells. J Clin Invest (1986) 2.21
Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am J Pathol (1992) 2.19
Precordial S-T segment elevation mapping: an atraumatic method for assessing alterations in the extent of myocardial ischemic injury. The effects of pharmacologic and hemodynamic interventions. Am J Cardiol (1972) 2.19
Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest (1999) 2.16
Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest (1999) 2.13
Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation (1997) 2.12
Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J Biol Chem (1995) 2.11
Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation (1998) 2.11
Effect of glucose-insulin-potassium infusion on myocardial infarction following experimental coronary artery occlusion. Circulation (1972) 2.10
An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation (2001) 2.09
PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol (1999) 2.07
The unstable atheroma. Arterioscler Thromb Vasc Biol (1997) 2.05
Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb (1991) 2.04
Culture of quiescent arterial smooth muscle cells in a defined serum-free medium. J Cell Physiol (1983) 2.03
Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest (1999) 2.03
PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation (1999) 2.02
Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol (1999) 2.00
Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci U S A (1995) 2.00
Death of smooth muscle cells and expression of mediators of apoptosis by T lymphocytes in human abdominal aortic aneurysms. Circulation (1999) 1.97
CD40 signaling and plaque instability. Circ Res (2001) 1.97
Host bone-marrow cells are a source of donor intimal smooth- muscle-like cells in murine aortic transplant arteriopathy. Nat Med (2001) 1.96
Leupeptin, a protease inhibitor, decreases protein degradation in normal and diseased muscles. Science (1978) 1.93
Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol (1992) 1.90
Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (1999) 1.86
Coronary artery reperfusion. I. Early effects on local myocardial function and the extent of myocardial necrosis. J Clin Invest (1972) 1.86
The relationship between inflammation, obesity and risk for hypertension in the Multi-Ethnic Study of Atherosclerosis (MESA). J Hum Hypertens (2010) 1.86
The impact of ethnicity and sex on subclinical cardiovascular disease: the Diabetes Heart Study. Diabetologia (2005) 1.84
Human coronary transplantation-associated arteriosclerosis. Evidence for a chronic immune reaction to activated graft endothelial cells. Am J Pathol (1991) 1.82
Fatty acid modulation of endothelial activation. Am J Clin Nutr (2000) 1.81
Interleukin 1 induces interleukin 1. II. Recombinant human interleukin 1 induces interleukin 1 production by adult human vascular endothelial cells. J Immunol (1987) 1.79
Inflammation and thrombosis: the clot thickens. Circulation (2001) 1.79
Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. J Clin Invest (1997) 1.77
Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in LDL receptor- deficient mice. J Clin Invest (1998) 1.76
Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. Circulation (1999) 1.74
Circumferential stress and matrix metalloproteinase 1 in human coronary atherosclerosis. Implications for plaque rupture. Arterioscler Thromb Vasc Biol (1996) 1.71
Novel inflammatory markers of coronary risk: theory versus practice. Circulation (1999) 1.65
Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: possible mediators of cardiovascular risk? J Cardiovasc Risk (2001) 1.65
Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. Am J Pathol (1997) 1.65
Inducible expression of class II major histocompatibility complex antigens and the immunogenicity of vascular endothelium. Transplantation (1986) 1.64
Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci U S A (2000) 1.63
Human interleukin 1 induces interleukin 1 gene expression in human vascular smooth muscle cells. J Exp Med (1987) 1.61
The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ Res (2000) 1.60
Inducible expression of vascular cell adhesion molecule-1 by vascular smooth muscle cells in vitro and within rabbit atheroma. Am J Pathol (1993) 1.58
Hyperlipidemia and atherosclerotic lesion development in LDL receptor-deficient mice fed defined semipurified diets with and without cholate. Arterioscler Thromb Vasc Biol (1999) 1.57
Expression of monocyte chemotactic protein and interleukin-8 by cytokine-activated human vascular smooth muscle cells. Arterioscler Thromb (1991) 1.57
HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol (2000) 1.56
Cytokine induction by lipopolysaccharide (LPS) corresponds to lethal toxicity and is inhibited by nontoxic Rhodobacter capsulatus LPS. Infect Immun (1990) 1.54
Implantation of vascular grafts lined with genetically modified endothelial cells. Science (1989) 1.54